ClinicalTrials.gg
RecruitingNCT06890273DUOLifeUpdated Sep 30, 2026

NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)

An observational study in Endometrial Cancer, sponsored by AstraZeneca. Recruiting at 49 sites in Germany. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by AstraZeneca · Observational

How we know · 3 judgments

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Endometrial Neoplasms by AstraZeneca — 9 open to participants now, 13 under way, 4 of them phase 3. Endometrial Neoplasms · AstraZeneca.

Started
2025
with 6 others
Observational
5 of 17
4 open now
Primary completion
2029-03
later than 11 of 12 live
Registered
12th of 17
by date

Among the 17 studies in Endometrial Neoplasms by AstraZeneca, this one is one of 7 that started in 2025, is one of 5 observational ones, reaches primary completion later than 11 of the 12 other live ones, and was the 12th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

9 of the 17 studies in Endometrial Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Endometrial Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

This is a German multi-center, prospective, non-interventional study (NIS) to collect real-world clinical data in patients with primary advanced (FIGO stage III or IV) or recurrent endometrial cancer (EC) receiving first-line (1L) regimens with Carboplatin/Paclitaxel/Durvalumab (CPD) followed by maintenance therapy with durvalumab or durvalumab and olaparib in line with the applicable european summary of product characteristics (SmPC). Additionally, patient-reported outcomes after 1L treatment with CPD will be assessed.

Read the detailed description

This is a multi-center, prospective, non-interventional study (NIS) to collect real-world clinical and PRO data in patients with primary advanced (FIGO stage III or IV) or recurrent EC receiving 1L CPD followed by maintenance therapy with durvalumab (DNA mismatch repair deficient; dMMR cohort) or durvalumab and olaparib (DNA mismatch repair proficient, pMMR cohort) in accordance with the applicable SmPC within routine clinical practice. Following surgery and/or radiation (if applicable) the decision to initiate 1L CPD followed by durvalumab or durvalumab and olaparib is made in a shared decision between the patient and the treating physician as part of routine care outside of and independent of this study.

The aim of the NIS is to describe the outcomes including effectiveness and safety of patients with primary advanced and recurrent EC treated with the two approved 1L regimens of CPD followed by durvalumab maintenance and CPD followed by durvalumab and olaparib maintenance, as well as patient-reported outcomes after chemotherapy-phase (CPD) in Germany. The study also aims to better understand characteristics of patients with primary advanced or recurrent EC that benefit from maintenance therapy with durvalumab or durvalumab and olaparib.

03

Conditions studied

  • Endometrial Cancer

Keywords

  • Durvalumab
  • Olaparib
  • Primary advanced endometrial cancer (1L)
  • FIGO III or IV
  • Recurrent endometrial cancer (1L)
  • dMMR
  • pMMR
  • Real-World Evidence
  • Patient-Reported Outcome
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

150 patients with documented primary advanced (FIGO stage III or IV) or recurrent EC of epithelial histology (excluding sarcomas) who are eligible for first-line therapy with CPD followed by durvalumab or durvalumab and olaparib in line with the applicable SmPC within routine clinical practice will be recruited in Germany. The study allows recruitment of patients that already started and may have received up to 2 cycles of CPD. Inclusion of patients having started CPD will be capped to 25% for each cohort of the study population. Testing results for MMR status of the patients' tumor must be available. Patients must be willing and able to report PROs. Eligible patients will be included into the study after and independently of the treating physician's treatment and diagnostic decisions.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged ≥ 18 years at the time of screening.
  • Patient has documented:
  • Primary advanced (FIGO III and IV) epithelial EC OR
  • Recurrent disease that is unlikely to be cured and where the multidisciplinary tumor board decision is systemic therapy. Carcinosarcomas are allowed,
  • Patient is intended or initiated to receive 1L CPD followed by maintenance therapy with durvalumab (dMMR cohort) or with durvalumab and olaparib (pMMR cohort) according to the SmPC of IMFINZI® and Lynparza®* prior to enrollment. Recruitment of patients that already started and may have received up to 2 cycles of CPD is allowed but will be capped to 25% for each cohort of the study population.
  • Patient is eligible for treatment with durvalumab and/or olaparib as specified in the IMFINZI® and Lynparza® SmPC. The prescription of the medicinal product is clearly separated from the decision to include the patient in the study.
  • MMR-testing results of the patient's tumor are known.
  • Patient is willing and able to complete PRO questionnaires.
  • Patient can read and understand German, English, Arab, Russian or Turkish.
  • Signed written .

Exclusion criteria

Exclusion Criteria:

  • Patient has already received >2 cycles of 1L CPD
  • Known to carboplatin, paclitaxel, durvalumab and/or olaparib or any of the of the drug.
  • Pregnancy or breast-feeding.
  • Unable to swallow orally administered medication.
  • Current or planned participation in an interventional clinical trial.
  • Current or planned systemic treatment of any tumor other than primary advanced or recurrent EC.
  • Patient has documented sarcoma
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • DNA mismatch repair deficient (dMMR)

    Patients with primary advanced or recurrent endometrial cancer receiving 1L regimens of CPD with prior tested dMMR status. Following the SmPC patients of this cohort will receive durvalumab in the maintenance phase if they achieved and maintained disease control, i.e., complete response (CR), partial response (PR), or stable disease (SD) with CPD during the chemotherapy phase.

  • DNA mismatch repair proficient (pMMR)

    Patients with primary advanced or recurrent endometrial cancer receiving 1L regimens of CPD with prior tested pMMR status. Following the SmPC patients of this cohort will receive durvalumab and olaparib in the maintenance phase if they achieved and maintained disease control i.e., CR, PR, or SD with CPD during the chemotherapy phase.

This study also gives DurvalumabStudies of DurvalumabDurvalumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., OlaparibStudies of OlaparibOlaparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Real-world Time To Next Treatment (rwTTNT)

    rwTTNT is defined as time from start of 1L CPD until first dose of next systemic therapy or start of any other next anticancer therapy or death from any cause. 1L maintenance therapy with durvalumab or durvalumab+olaparib is not considered as next systemic therapy. The measure of interest is the landmark at 12 months of time to first next therapy or death (rwTTNT).

    Time frame: At 12 months

Secondary outcomes

  1. Real-world Progression-free Survival (rwPFS)

    rwPFS is defined as time from start of 1L CPD until progression or death from any cause. The measure of interest is the landmark at 12 months of progression-free survival (rwPFS).

    Time frame: At 12 months

  2. Time to deterioration in health-related quality of life (HRQoL) based on EORTC QLQ-C30 questionnaire compared to baseline over time

    The European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30), is a validated 30-item self-administered core questionnaire designed to assess HRQoL, functioning, and symptoms in all cancer patients or survivors. Time to deterioration is defined as time from baseline (≤ 14 days before first application of maintenance therapy) to date of first clinically meaningful deterioration i.e. a decrease by ≥10 points for the functional scales and an increase by ≥ 10 points for the symptom scales or death in: * Physical functioning score * Role functioning score

    Time frame: Baseline to first clinically meaningful deterioration, up to 46 months

  3. Time to deterioration in HRQoL based on EORTC QLQ-EN24 questionnaire compared to baseline over time

    The Endometrial Cancer Module EORTC QLQ-EN24, is a validated disease-specific extension to the EORTC QLQ-C30 designed to assess disease and treatment specific aspects of the QoLof patients with all stages of EC. The module consists of 24 questions grouped into 13 scales. Time to deterioration is defined as time from baseline (≤ 14 days before first application of maintenance therapy) to date of first clinically meaningful deterioration i.e. a decrease by ≥10 points for the functional scales and an increase by ≥ 10 points for the symptom scales or death in: * Back/pelvic pain * Gastrointestinal (GI) symptoms * Urological symptoms

    Time frame: Baseline to first clinically meaningful deterioration, up to 46 months

  4. Duration of maintenance therapy

    Time from first dose of maintenance therapy with durvalumab or durvalumab+olaparib to the last dose/cyle of durvalumab or olaparib, whatever is last, including number and duration of treatment interruptions.

    Time frame: From first dose of maintenance therapy up to 46 months

  5. Duration of 1L CPD

    Duration of therapy with durvalumab with carboplatin and/or paclitaxel

    Time frame: Assessed up to 46 months

  6. Time between end of CPD until start of maintenance therapy

    Time to start maintenance therapy defined as date of last cycle of chemotherapy until date of first dose of maintenance therapy

    Time frame: Assessed up to 46 months

  7. Usage of treatment therapy

    Dose, dose change, treatment interruption, number of cycles, cumulative dose of durvalumab.

    Time frame: Assessed up to 46 months

Other outcomes

  1. Safety: Collection of Adverse Events (AE)

    Safety evaluated based on type of Adverse Event (AE), intensity, causal relationship to treatment, duration, handling, outcome, and seriousness.

    Time frame: During routine visits up to 46 months

  2. Change in timed up and go test (TUG)

    The Timed up and go test (TUG) is a reliable and validated measure of functional mobility that can be used to assess frailty and functional impairment and to predict the risk of postoperative complications. The TUG records the time it takes a patient to get up from an armchair, walk 3 meters, turn around, walk back, and sit down again. Aids such as walking aids are permitted but help from other people is not. TUG should be assesd at every routine visit.

    Time frame: Baseline up to 46 months

  3. Change in EORTC QLQ-C30

    Changes of patient-reported outcomes (PROs) based on the European Organisation for Research and Treatment of Cancer Quality of Life - Core Questionnaire 30 (EORTC QLQ-C30) questionnaire from baseline (defined as ≤ 14 days before first application of maintenance therapy) over time in: * Physical functioning score of EORTC QLQC30 * Role functioning score of the EORTC QLQ-C30 * Global health status/quality of life (QoL) score of the EORTC QLQ-C30 * All other functioning and symptom subscale scores of the EORTC QLQ-C30.

    Time frame: Baseline up to 46 months

07

Study locations

49 of 49 sites recruiting
  • Research Site
    Amberg, Germany
    Recruiting
  • Research Site
    Bad Nauheim, Germany
    Recruiting
  • Research Site
    Bautzen, Germany
    Recruiting
  • Research Site
    Berlin, Germany
    Recruiting
  • Research Site
    Bielefeld, Germany
    Recruiting
  • Research Site
    Bonn, Germany
    Recruiting
  • Research Site
    Borna, Germany
    Recruiting
  • Research Site
    Bottrop, Germany
    Recruiting
  • Research Site
    Brandenburg an der Havel, Germany
    Recruiting
  • Research Site
    Braunschweig, Germany
    Recruiting
  • Research Site
    Cologne, Germany
    Recruiting
  • Research Site
    Dessau, Germany
    Recruiting
  • Research Site
    Dresden, Germany
    Recruiting
  • Research Site
    Ebersberg, Germany
    Recruiting
  • Research Site
    Eggenfelden, Germany
    Recruiting
  • Research Site
    Essen, Germany
    Recruiting
  • Research Site
    Goslar, Germany
    Recruiting
  • Research Site
    Greifswald, Germany
    Recruiting
  • Research Site
    Gütersloh, Germany
    Recruiting
  • Research Site
    Hamburg, Germany
    Recruiting
  • Research Site
    Heilbronn, Germany
    Recruiting
  • Research Site
    Homburg, Germany
    Recruiting
  • Research Site
    Hösbach, Germany
    Recruiting
  • Research Site
    Kiel, Germany
    Recruiting
  • Research Site
    Krefeld, Germany
    Recruiting
  • Research Site
    Kulmbach, Germany
    Recruiting
  • Research Site
    Landshut, Germany
    Recruiting
  • Research Site
    Leipzig, Germany
    Recruiting
  • Research Site
    Limburg, Germany
    Recruiting
  • Research Site
    Lüneburg, Germany
    Recruiting
  • Research Site
    Magdeburg, Germany
    Recruiting
  • Research Site
    Mainz, Germany
    Recruiting
  • Research Site
    München, Germany
    Recruiting
  • Research Site
    Neuruppin, Germany
    Recruiting
  • Research Site
    Neuss, Germany
    Recruiting
  • Research Site
    Nuremberg, Germany
    Recruiting
  • Research Site
    Plauen, Germany
    Recruiting
  • Research Site
    Rotenburg (Wümme), Germany
    Recruiting
  • Research Site
    Siegen, Germany
    Recruiting
  • Research Site
    Solingen, Germany
    Recruiting
  • Research Site
    Stendal, Germany
    Recruiting
  • Research Site
    Torgau, Germany
    Recruiting
  • Research Site
    Traunstein, Germany
    Recruiting
  • Research Site
    Unna, Germany
    Recruiting
  • Research Site
    Wernigerode, Germany
    Recruiting
  • Research Site
    Winnenden, Germany
    Recruiting
  • Research Site
    Witten, Germany
    Recruiting
  • Research Site
    Worms, Germany
    Recruiting
  • Research Site
    Zittau, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved, AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Mar 2029, 46 months after the start.

Of 150 observational studies under Endometrial Neoplasms, half reached primary completion within 105 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 206. This study's planned 46 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Mar 24, 2025
StartActual
May 20, 2025
Primary completionEst.
Mar 31, 2029
CompletionEst.
Mar 31, 2029
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06890273
Lead sponsor
AstraZeneca
Collaborators
North-Eastern German Society of Gynecological Oncology (NOGGO e.V.)
Responsible party
Sponsor
First posted
Mar 24, 2025
Start date
May 20, 2025
Primary completion
Mar 31, 2029 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Sep 30, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion